BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

853 related articles for article (PubMed ID: 29562192)

  • 1. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape.
    Wellenstein MD; de Visser KE
    Immunity; 2018 Mar; 48(3):399-416. PubMed ID: 29562192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy.
    Lian X; Yang K; Li R; Li M; Zuo J; Zheng B; Wang W; Wang P; Zhou S
    Mol Cancer; 2022 Jan; 21(1):27. PubMed ID: 35062950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance.
    Traba J; Sack MN; Waldmann TA; Anton OM
    Front Immunol; 2021; 12():657293. PubMed ID: 34079545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
    Puré E; Lo A
    Cancer Immunol Res; 2016 Apr; 4(4):269-78. PubMed ID: 27036971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Immune Cell Lineage Reprogramming in Cancer.
    Leavenworth JW; Shi LZ; Wang X; Wei H
    Front Immunol; 2021; 12():838464. PubMed ID: 35126385
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunosuppressive cells in tumor immune escape and metastasis.
    Liu Y; Cao X
    J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy-induced microenvironmental changes in cancer.
    Ma Y; Yang H; Pitt JM; Kroemer G; Zitvogel L
    J Mol Med (Berl); 2016 May; 94(5):497-508. PubMed ID: 26931513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteoglycans and Immunobiology of Cancer-Therapeutic Implications.
    Tzanakakis G; Neagu M; Tsatsakis A; Nikitovic D
    Front Immunol; 2019; 10():875. PubMed ID: 31068944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoxidation and cancer immunity.
    Martín-Sierra C; Laranjeira P; Domingues MR; Paiva A
    Redox Biol; 2019 May; 23():101103. PubMed ID: 30658904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Regulation and Antitumor Effect of TIM-1.
    Du P; Xiong R; Li X; Jiang J
    J Immunol Res; 2016; 2016():8605134. PubMed ID: 27413764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
    Cui Y; Guo G
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy.
    Meng MB; Wang HH; Cui YL; Wu ZQ; Shi YY; Zaorsky NG; Deng L; Yuan ZY; Lu Y; Wang P
    Oncotarget; 2016 Aug; 7(35):57391-57413. PubMed ID: 27429198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Expanding World of N-MYC-Driven Tumors.
    Rickman DS; Schulte JH; Eilers M
    Cancer Discov; 2018 Feb; 8(2):150-163. PubMed ID: 29358508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
    Reiser J; Banerjee A
    J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing mutational and adaptive landscapes and the genesis of cancer.
    Liggett LA; DeGregori J
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):84-94. PubMed ID: 28167050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-related interleukins: old validated targets for new anti-cancer drug development.
    Setrerrahmane S; Xu H
    Mol Cancer; 2017 Sep; 16(1):153. PubMed ID: 28927416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of fatty acid metabolism in tumourigenesis: Beyond providing nutrition (Review).
    Yu XH; Ren XH; Liang XH; Tang YL
    Mol Med Rep; 2018 Dec; 18(6):5307-5316. PubMed ID: 30365095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.
    Andrews MC; Reuben A; Gopalakrishnan V; Wargo JA
    Front Immunol; 2018; 9():946. PubMed ID: 29780391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-based identification of cancer patients at high risk of progression.
    Vano YA; Petitprez F; Giraldo NA; Fridman WH; Sautès-Fridman C
    Curr Opin Immunol; 2018 Apr; 51():97-102. PubMed ID: 29554496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fundamental role of mechanical properties in the progression of cancer disease and inflammation.
    Mierke CT
    Rep Prog Phys; 2014 Jul; 77(7):076602. PubMed ID: 25006689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.